Hormone therapy for postmenopausal osteoporosis management.

Area of Science:

• Reproductive Endocrinology
• Bone Metabolism
• Clinical Pharmacology

Background:

• Menopausal hormone therapy (MHT) has a long history in managing postmenopausal osteoporosis.
• Public safety concerns arose following the 2002 Women's Health Initiative report.
• Re-evaluation of evidence is crucial for informed clinical practice.

Purpose of the Study:

• To conduct a historical review of menopausal hormone therapy for postmenopausal osteoporosis.
• To summarize high-quality evidence on MHT's efficacy and safety.
• To discuss clinical considerations for MHT initiation, patient selection, duration, and discontinuation.

Main Methods:

• Focus on Level I evidence, including randomized controlled trials.
• Inclusion of systematic reviews and meta-analyses.
• Historical review and synthesis of existing data.

Main Results:

• High-quality evidence supports the efficacy of MHT in preventing and treating postmenopausal osteoporosis.
• Current evidence indicates a favorable safety profile when used appropriately.
• Clinical guidelines address initiation, candidate selection, duration, and discontinuation.

Conclusions:

• Menopausal hormone therapy remains a valuable option for managing postmenopausal osteoporosis.
• Careful patient selection and individualized treatment plans are essential.
• Ongoing evaluation of risks and benefits guides MHT use.